Antiviral therapies for respiratory syncytial virus infection: current expectations

Key Points

• Antiviral drugs can reduce acute disease severity in respiratory syncytial virus cases, potentially improving health outcomes.
• Current therapies are inadequate in addressing long-term respiratory morbidity associated with RSV infections.
• Reviewing existing antiviral options underscores the need for innovative therapeutic drugs targeting RSV.
• Developing new treatments may significantly impact public health by reducing both immediate and future respiratory complications.